Brown & Brown: Acquisitions Fuel EPS Growth

Brown & Brown is rated Buy despite a 0.7% organic revenue decline in Q2 2026, as bolt-on acquisitions are expected to offset softer underlying growth. Its scale and BBB- credit rating support accretive M&A, underpinning projected 7.5% annual EPS growth through 2028 despite declining CAT rates. At a 15.24x forward P/E, below its 10-year average, the shares are assessed to have 26% upside to a $90 fair value.

Analysis

BRO's investment case is shifting from a premium organic-compounder narrative toward a capital-allocation story. That can support earnings in the next 12-24 months, but only if acquired revenue is bought below BRO's own valuation and integration preserves producer retention; otherwise, reported EPS growth may mask deteriorating core franchise economics. Softening property-catastrophe pricing is particularly relevant because brokers face lower commission yield even if insured values and exposure units continue to rise.

Relative to AON, AJG and WTW, BRO has more room for multiple recovery if organic growth reaccelerates, but its lower credit rating makes debt-funded consolidation more sensitive to acquisition multiples and refinancing costs. The key near-term catalyst is a return to positive organic growth in the next two quarterly prints, not another deal announcement; the market will increasingly discount inorganic growth if leverage rises faster than EBITDA. A 1-3 month downside risk is further commercial-rate deceleration, while the 6-18 month upside case rests on a resilient middle-market exposure base and disciplined bolt-on execution.

Consensus may be underweight the possibility that a declining-rate environment produces an earnings-quality discount rather than a valuation rerating. Insurance brokerage multiples historically depend on recurring organic growth and low capital intensity; if BRO must deploy materially more capital to maintain growth, free-cash-flow conversion and return on invested capital become more important than headline EPS. This is therefore attractive only as a selective relative-value long, with position sizing contingent on acquisition consideration, net leverage, and producer-retention disclosure.

Key Decisions for Investors

• Initiate a modest long BRO / short WTW pair over a 6-12 month horizon if BRO reports positive organic growth next quarter; BRO offers more potential multiple normalization, while WTW is more exposed to a broad brokerage valuation de-rating. Exit if BRO organic growth remains negative for a second consecutive quarter or net leverage moves materially above management's historical range.
• Do not chase BRO solely on acquisition announcements. Add only after reviewing purchase-price multiples, earn-out structure and post-deal leverage; a deal funded at elevated revenue multiples without corresponding margin accretion would invalidate the accretive-M&A thesis.
• Use AON and AJG as read-through hedges: if commercial P&C pricing weakens faster than expected, reduce BRO exposure or express the view through long AJG / short BRO, as AJG's larger scale and acquisition engine may better absorb a lower-commission-rate environment.
• Set an earnings alert around organic revenue growth, adjusted EBITDA margin, net-debt-to-EBITDA and acquisition spend. A return to 2%+ organic growth with stable margins supports a 12-month rerating case; continued contraction or margin erosion would likely cap upside despite reported EPS growth.